Partnering with
MOGRIFY
Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, ex vivo cell therapy and in vivo reprogramming therapy to develop treatments for indications of high unmet clinical need. We are particularly interested in speaking with those with interest in hematological, immunological, ophthalmological as well as other disease areas where these modalities may be of interest. Mogrify is commercializing its technology via a combination of internal therapy development, co-development partnerships, and out-licensing of novel cell conversions applicable to non-core markets.
Current
PARTNERS
Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, cell therapy, and genome engineering.
MRC Laboratory for Molecular Biology
The MRC Laboratory of Molecular Biology (LMB) is a research institute dedicated to the understanding of important biological processes at the levels of atoms, molecules, cells and organisms. In doing so, they provide knowledge needed to solve key problems in human health.
Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology
Duke-NUS Medical School
Duke-NUS Medical School is a research powerhouse and our distinguished scientists are transforming the way we understand, diagnose and treat diseases. Our founder, Assistant Professor, Owen Rackham, and his group at the School focus on what defines human cells and how their phenotype emerges from the complex interplay between the genome, transcriptome and environment. Developing methods that leverage the large volume of gene expression, epigenetic and interaction data that is being generated to develop biological hypotheses about how certain perturbations can influence cell fate.
Monash University
The Polo Laboratory, a part of the Monash Biomedicine Discovery Institute at Monash University, focuses on the transcriptional and epigenetic mechanisms that govern cell identity, in particular, pluripotency and the reprogramming of somatic cells into induced pluripotent stem (iPS) cells.
Our
PIPELINE
| AREA | Sample Acquisition | Bioinformatics | In vitro PoC | In vivo PoC | IND | Clinical | Marketing |
|---|---|---|---|---|---|---|---|
| Ophthalmology | mogrify | mogrify | mogrify | partner | partner | ||
| Immunology (& hematology) |
mogrify | mogrify | mogrify | mogrify | partner | partner | |
| Collaborations (Pancreatic, Lung, Immune & Others) |
mogrify | mogrify | mogrify | partner | partner | partner | partner |
| mogrify | Mogrify Progress | partner | Expect to Partner |
Upcoming
Events & Conferences
Discover an Epigenetics Approach to Driving Cell Identity and Scalability in Cell Therapy.
The fifteenth annual BIO-Europe Spring® premier springtime partnering conference will be held March 22-25 in a fully digital format.
The theme of the 2021 ARVO Annual Meeting is the next revolution of clinically translating these discoveries to restore and preserve vision.
Join ASGCT for the field’s premier event, and take in the cutting edge science with leaders from academia, medicine, industry, advocacy, and more.
The first ELRIG meeting on Advances in Cell and Gene Therapies will be held on the 18th and 19th of May 2021 virtually. This interactive 2-day conference will host world-leading scientists from academia and industry to discuss current and future perspectives of Cell and Gene Therapies.
Join the BIO International Convention 2021 to find innovative collaborations and partnerships.
The ISSCR Annual Meeting gathers the world’s leading scientists, clinicians, business leaders, ethicists, and educators from more than 65 countries. Together, we represent the full spectrum of stem cell science and regenerative medicine. Discovery, new business, careers, advocacy, and relationships start here.
We are proud to be sponsoring the Cambridge International Stem Cell Symposium in September 2021.